CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 2.8: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
301.55MUSDvs all stocks (USD)
Revenue (TTM)
57.80MUSDvs all stocks (USD)
Profit Margin
-62.40%vs Medical Devices peers
Beta
0.6280xvs all stocks
52-Week Change
5.60%vs all stocks
Market Capitalization
301.55MUSDvs all stocks (USD)
Enterprise Value
172.92MUSDvs all stocks (USD)
Forward P/E
-25.85xvs Medical Devices peers
Price to Sales (TTM)
5.26xvs Medical Devices peers
Price to Book (MRQ)
2.07xvs Medical Devices peers
Enterprise to Revenue
2.99xvs Medical Devices peers
Enterprise to EBITDA
-9.16xvs Medical Devices peers
Gross Margin
51.43%vs Medical Devices peers
Profit Margin
-62.40%vs Medical Devices peers
Operating Margin
-48.60%vs Medical Devices peers
Return on Assets (TTM)
-7.58%vs Medical Devices peers
Return on Equity (TTM)
-24.11%vs Medical Devices peers
Revenue (TTM)
57.80MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.59USDUpdated Jul 19, 2026Quarterly Revenue Growth
13.60%vs Medical Devices peers
Gross Profit (TTM)
30.06MUSDvs all stocks (USD)
EBITDA (TTM)
-18.88MUSDvs all stocks (USD)
Net Income (TTM)
-35.40MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.62%vs Medical Devices peers
Operating Cash Flow (TTM)
-7.46MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
56.20MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
27.77MUSDFY2025 · Dec 31, 2025Gross Profit
28.42MUSDFY2025 · Dec 31, 2025Operating Income
-25.68MUSDvs all stocks (USD)
Pre-tax Income
-33.34MUSDFY2025 · Dec 31, 2025Income Tax Expense
-66.00KUSDFY2025 · Dec 31, 2025Net Income
19.49MUSDFY2025 · Dec 31, 2025EBIT
-25.68MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.47MUSDFY2025 · Dec 31, 2025Research & Development
15.57MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
38.53MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.14MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
19.49MUSDFY2025 · Dec 31, 2025Operating Cash Flow
41.12MUSDFY2025 · Dec 31, 2025Free Cash Flow
40.17MUSDDerived from operating cash flow minus capital expenditure. This filing charges 4.47M of depreciation against 955K of capital expenditure, and its own free-cash-flow line reads -24.64M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
70.59MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
19.49MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.46MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
9.85MUSDFY2025 · Dec 31, 2025Other Non-cash Items
13.74MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
220.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.64MUSDFY2025 · Dec 31, 2025Capital Expenditures
-955.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
67.91MUSDFY2025 · Dec 31, 2025Purchase of Investments
-64.00MUSDFY2025 · Dec 31, 2025Sale of Investments
47.80MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
50.75MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.56MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-697.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
37.41MSharesUpdated Jul 19, 2026Float Shares
24.19MSharesUpdated Jul 19, 2026Shares Short
3.08MSharesUpdated Jul 19, 2026Short Ratio
9.12daysvs all stocks
Short % of Shares Outstanding
17.39%vs all stocks
% Held by Insiders
8.21%vs all stocks
% Held by Institutions
82.81%vs all stocks
Total Cash (MRQ)
111.74MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.96USDUpdated Jul 19, 2026Total Debt (MRQ)
4.47MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0333xvs Medical Devices peers
Current Ratio (MRQ)
3.58xvs Medical Devices peers
Book Value per Share (MRQ)
3.59USDUpdated Jul 19, 2026Total Assets
190.07MUSDvs all stocks (USD)
Total Current Assets
144.56MUSDFY2025 · Dec 31, 2025Total Liabilities
46.37MUSDFY2025 · Dec 31, 2025Total Non-current Assets
45.51MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
12.31MUSDFY2025 · Dec 31, 2025Total Current Liabilities
34.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
70.52MUSDFY2025 · Dec 31, 2025Other Short-term Investments
42.45MUSDFY2025 · Dec 31, 2025Accounts Receivable
11.33MUSDFY2025 · Dec 31, 2025Inventory
12.99MUSDFY2025 · Dec 31, 2025Accounts Payable
1.59MUSDFY2025 · Dec 31, 2025Short-term Debt
681.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
8.93MUSDFY2025 · Dec 31, 2025Other Current Liabilities
16.02MUSDFY2025 · Dec 31, 2025Long-term Debt
3.95MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
30.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
36.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-223.32MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
143.70MUSDvs all stocks (USD)
52-Week Low
5.03USDUpdated Jul 19, 202652-Week High
9.34USDUpdated Jul 19, 202652-Week Change
5.60%vs all stocks
Beta
0.6280xvs all stocks
50-Day MA
8.13USDUpdated Jul 19, 2026200-Day MA
7.06USDUpdated Jul 19, 2026Avg 10-Day Volume
221.09KSharesUpdated Jul 19, 2026Avg 30-Day Volume
295.58KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.9700USDUpdated Jul 19, 2026Other Income / Expense
-11.80MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.51Profit Margin: -0.62
Financial Health
Altman Z-Score 2.8: safe zoneNotable
Altman Z-Score: 2.80
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
JBM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
Hikal Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Essex Bio-Technology Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Huangshan Capsule Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Neumora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Il Dong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Mastercard Incorporated
2 interpretationsCash-Flow Ratios ElevatedFCF Ratios Elevated
Jiangsu Sihuan Bioengineering Co., Ltd.
2 interpretationsCash-Flow Ratios ElevatedFCF Ratios Elevated
IIFL Finance Ltd.
2 interpretationsCash-Flow Ratios ElevatedFCF Ratios Elevated